查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1790329

美國糖尿病酮酸症治療市場規模、佔有率和趨勢分析報告：按療法、最終用途、地區和細分市場預測，2025 年至 2033 年

U.S. Diabetic Ketoacidosis Treatment Market Size, Share & Trends Analysis Report By Treatment (Fluid Replacement Therapy, Electrolyte Replacement Therapy), By End Use (Hospital, Homecare Settings), By Region, And Segment Forecasts, 2025 - 2033
出版日期: | 出版商: Grand View Research | 英文 150 Pages | 商品交期: 2-10個工作天內

價格

市場規模和趨勢

預計 2024 年美國糖尿病酮酸症治療市場規模為 2.6143 億美元，到 2033 年將達到 3.7439 億美元，2025 年至 2033 年的複合年成長率為 4.07%。

這一成長是由美國人口整體中第1型糖尿病和胰島素依賴型2型糖尿病盛行率的上升所驅動。這種成長導致與急性糖尿病併發症（尤其是糖尿病酮酸症）相關的住院人數增加。人們越來越意識到早期糖尿病酮症酸中毒管理和及時介入的重要性，這也促進了這一成長。

急救基礎設施的進步以及速效胰島素治療和輸液的普及進一步推動了這種擴張。例如，2025年1月，《印度重症監護醫學雜誌》在PubMed上發表了一篇綜述文章（PMID：39802248），顯示平衡電解質溶液可使成年糖尿病酮症酸中毒 (DKA) 患者的碳酸氫鹽水平升高1.63 mmol/L，氯化物水平降低2.37 mmol/L。標準化醫院治療通訊協定的日益普及正在改善美國醫療機構對糖尿病酮酸症的管理。醫院正在採用結構化的指南，概述輸液、胰島素治療和電解質矯正，以確保及時一致的治療。例如，2023年12月，美國糖尿病協會在《糖尿病護理》雜誌上發表了“2024年糖尿病護理標準”，重點介紹了管理糖尿病酮症酸中毒和高血糖高血脂狀態的最新指南。該指南強調液體、胰島素和電解質治療的結構化方案，目的是減少治療的變異性並改善美國醫療保健的患者預後。

長效胰島素類似物可實現更穩定的血糖控制並減少給藥頻率，從而降低出院後糖尿病酮症酸中毒 (DKA) 復發的風險。速效靜脈胰島素製劑對於急診急性發作的有效管理仍然至關重要。胰島素製劑與其他降血糖藥物的聯合治療因其在復健和長期管理中的顯著益處而備受關注。例如，美國兒科藥學協會於2024年12月發表了一項題為「糖尿病酮酸中毒危重病患兒早期與晚期啟動長效胰島素的回顧性比較」(PMCID: PMC11627569) 的研究。研究納入了233例病例，發現早期和晚期啟動Insulin Glargine治療在酸中毒緩解時間、住院時長或併發症發生率方面均無顯著差異。結果表明，啟動時間並不影響兒童DKA治療的臨床療效。

目錄

第1章調查方法與範圍

第2章執行摘要

第3章美國糖尿病酮酸症治療市場變數、趨勢與範圍

  • 市場體系展望
  • 市場動態
    • 市場促進因素分析
    • 市場限制因素分析
  • 商業環境分析
    • 產業分析—波特五力分析
    • PESTLE分析
    • 管道分析
    • 專利到期分析
    • 定價分析

第4章美國糖尿病酮酸症治療市場：治療業務分析

  • 2024年和2033年的治療市場佔有率
  • 治療細分儀表板
  • 市場規模、預測與趨勢分析（按治療，2021-2033 年）
  • 液體替代療法
  • 電解質替代療法
  • 胰島素治療
  • 其他

第5章美國糖尿病酮酸症治療市場：最終用途業務分析

  • 2024年和2033年的最終用途市場佔有率
  • 最終用途細分儀表板
  • 按最終用途分類的市場規模、預測和趨勢分析（2021-2033 年）
  • 醫院
  • 門診手術中心（ASC）
  • 居家照護

第6章 競爭態勢

  • 參與者概覽
  • 企業市場分析
  • 公司分類
  • 戰略地圖
  • 公司簡介/上市公司
    • Novo Nordisk
    • Eli Lilly and Company
    • Sanofi
    • Pfizer Inc.
    • Baxter International Inc.
    • B. Braun Melsungen AG
    • Hikma Pharmaceuticals
    • Teva Pharmaceutical Industries Ltd.
    • Fresenius Kabi
    • Biocon
Product Code: GVR-4-68040-658-5

Market Size & Trends:

The U.S. diabetic ketoacidosis treatment market size was estimated at USD 261.43 million in 2024 and is projected to reach USD 374.39 million by 2033, growing at a CAGR of 4.07% from 2025 to 2033. This growth is driven by the increasing incidence of type 1 and insulin-dependent type 2 diabetes across the U.S. population. This rise has led to higher hospital admissions related to acute diabetic complications, particularly diabetic ketoacidosis. This growth is also supported by greater awareness of early DKA management and the importance of timely intervention.

This expansion is further fueled by advancements in emergency care infrastructure and the availability of rapid-acting insulin therapies and intravenous fluid solutions. For instance, in January 2025, the Indian Journal of Critical Care Medicine published a review on PubMed (PMID: 39802248) showing that balanced electrolyte solutions increased bicarbonate by 1.63 mmol/L and reduced chloride by 2.37 mmol/L in adult DKA patients. The increasing adoption of standardized hospital treatment protocols is improving the management of diabetic ketoacidosis across U.S. healthcare facilities. Hospitals utilize structured guidelines outlining fluid replacement, insulin therapy, and electrolyte correction to ensure timely and consistent care. For instance, in December 2023, the American Diabetes Association published its Standards of Care in Diabetes 2024 in Diabetes Care, highlighting updated guidelines for managing diabetic ketoacidosis and hyperglycemic hyperosmolar state. The guidance emphasized structured protocols for fluid, insulin, and electrolyte therapy. It aimed to reduce treatment variability and improve patient outcomes across U.S. healthcare settings.

Pharmaceutical advancements in insulin therapy are significantly strengthening the diabetic ketoacidosis treatment landscape in the U.S. Long-acting insulin analogs enable more stable glycemic control and reduce the frequency of administration, lowering the risk of DKA recurrence after discharge. Rapid-acting intravenous insulin formulations remain critical in emergency care settings for managing acute episodes effectively. Combination treatment options, including insulin and other glucose-lowering agents, are gaining attention for their extended benefits in recovery and long-term management. For instance, in December 2024, the Pediatric Pharmacy Association published a study titled Retrospective Comparison of Early Versus Late Initiation of Long-Acting Insulin in Critically Ill Pediatric Patients in Diabetic Ketoacidosis (PMCID: PMC11627569). It reviewed 233 cases and found no significant difference in acidosis resolution time, hospital stay, or complication rates between early and late insulin glargine initiation. The results indicated that timing did not affect clinical outcomes in pediatric DKA care.

U.S. Diabetic Ketoacidosis Treatment Market Report Segmentation

This report forecasts revenue growth for the U.S. and provides an analysis of the latest industry trends in each of the sub-segments from 2021 to 2033. For this study, Grand View Research has segmented the U.S. diabetic ketoacidosis treatment market report based on treatment, and end use:

  • Treatment Outlook (Revenue, USD Million, 2021 - 2033)
  • Fluid Replacement Therapy
  • Electrolyte Replacement Therapy
  • Insulin Therapy
  • Others
  • End Use Outlook (Revenue, USD Million, 2021 - 2033)
  • Hospital
  • Ambulatory Surgical Centers (ASCs)
  • Homecare Settings

Table of Contents

Chapter 1. Methodology and Scope

  • 1.1. Market Segmentation & Scope
  • 1.2. Segment Definitions
    • 1.2.1. Treatment
    • 1.2.2. End Use
  • 1.3. Estimates and Forecast Timeline
  • 1.4. Research Methodology
  • 1.5. Information Procurement
    • 1.5.1. Purchased Database
    • 1.5.2. GVR's Internal Database
    • 1.5.3. Secondary Sources
    • 1.5.4. Primary Research
  • 1.6. Information Analysis
    • 1.6.1. Data Analysis Models
  • 1.7. Market Formulation & Data Visualization
  • 1.8. Model Details
    • 1.8.1. Commodity Flow Analysis
  • 1.9. List of Secondary Sources
  • 1.10. Objectives

Chapter 2. Executive Summary

  • 2.1. Market Snapshot
  • 2.2. Segment Snapshot
  • 2.3. Competitive Landscape Snapshot

Chapter 3. U.S. Diabetic Ketoacidosis Treatment Market Variables, Trends, & Scope

  • 3.1. Market Lineage Outlook
  • 3.2. Market Dynamics
    • 3.2.1. Market Driver Analysis
    • 3.2.2. Market Restraint Analysis
  • 3.3. Business Environment Analysis
    • 3.3.1. Industry Analysis - Porter's Five Forces Analysis
      • 3.3.1.1. Supplier Power
      • 3.3.1.2. Buyer Power
      • 3.3.1.3. Substitution Threat
      • 3.3.1.4. Threat of New Entrants
      • 3.3.1.5. Competitive Rivalry
    • 3.3.2. PESTLE Analysis
    • 3.3.3. Pipeline Analysis
    • 3.3.4. Patent Expiry Analysis
    • 3.3.5. Pricing Analysis

Chapter 4. U.S. Diabetic Ketoacidosis Treatment Market: Treatment Business Analysis

  • 4.1. Treatment Market Share, 2024 & 2033
  • 4.2. Treatment Segment Dashboard
  • 4.3. Market Size & Forecasts and Trend Analysis, by Treatment, 2021 to 2033 (USD Million)
  • 4.4. Fluid Replacement Therapy
    • 4.4.1. Fluid Replacement Therapy Market, 2021 - 2033 (USD Million)
  • 4.5. Electrolyte Replacement Therapy
    • 4.5.1. Electrolyte Replacement Therapy Market, 2021 - 2033 (USD Million)
  • 4.6. Insulin Therapy
    • 4.6.1. Insulin Therapy Market, 2021 - 2033 (USD Million)
  • 4.7. Others
    • 4.7.1. Others Market, 2021 - 2033 (USD Million)

Chapter 5. U.S. Diabetic Ketoacidosis Treatment Market: End Use Business Analysis

  • 5.1. End Use Market Share, 2024 & 2033
  • 5.2. End Use Segment Dashboard
  • 5.3. Market Size & Forecasts and Trend Analysis, by End Use, 2021 to 2033 (USD Million)
  • 5.4. Hospitals
    • 5.4.1. Hospitals Market, 2021 - 2033 (USD Million)
  • 5.5. Ambulatory Surgical Centers (ASCs)
    • 5.5.1. Ambulatory Surgical Centers (ASCs) Market, 2021 - 2033 (USD Million)
  • 5.6. Homecare Settings
    • 5.6.1. Homecare Settings Market, 2021 - 2033 (USD Million)

Chapter 6. Competitive Landscape

  • 6.1. Participant Overview
  • 6.2. Company Market Position Analysis
  • 6.3. Company Categorization
  • 6.4. Strategy Mapping
  • 6.5. Company Profiles/Listing
    • 6.5.1. Novo Nordisk
      • 6.5.1.1. Overview
      • 6.5.1.2. Financial Performance
      • 6.5.1.3. Treatment Benchmarking
      • 6.5.1.4. Strategic Initiatives
    • 6.5.2. Eli Lilly and Company
      • 6.5.2.1. Overview
      • 6.5.2.2. Financial Performance
      • 6.5.2.3. Treatment Benchmarking
      • 6.5.2.4. Strategic Initiatives
    • 6.5.3. Sanofi
      • 6.5.3.1. Overview
      • 6.5.3.2. Financial Performance
      • 6.5.3.3. Treatment Benchmarking
      • 6.5.3.4. Strategic Initiatives
    • 6.5.4. Pfizer Inc.
      • 6.5.4.1. Overview
      • 6.5.4.2. Financial Performance
      • 6.5.4.3. Treatment Benchmarking
      • 6.5.4.4. Strategic Initiatives
    • 6.5.5. Baxter International Inc.
      • 6.5.5.1. Overview
      • 6.5.5.2. Financial Performance
      • 6.5.5.3. Treatment Benchmarking
      • 6.5.5.4. Strategic Initiatives
    • 6.5.6. B. Braun Melsungen AG
      • 6.5.6.1. Overview
      • 6.5.6.2. Financial Performance
      • 6.5.6.3. Treatment Benchmarking
      • 6.5.6.4. Strategic Initiatives
    • 6.5.7. Hikma Pharmaceuticals
      • 6.5.7.1. Overview
      • 6.5.7.2. Financial Performance
      • 6.5.7.3. Treatment Benchmarking
      • 6.5.7.4. Strategic Initiatives
    • 6.5.8. Teva Pharmaceutical Industries Ltd.
      • 6.5.8.1. Overview
      • 6.5.8.2. Financial Performance
      • 6.5.8.3. Treatment Benchmarking
      • 6.5.8.4. Strategic Initiatives
    • 6.5.9. Fresenius Kabi
      • 6.5.9.1. Overview
      • 6.5.9.2. Financial Performance
      • 6.5.9.3. Treatment Benchmarking
      • 6.5.9.4. Strategic Initiatives
    • 6.5.10. Biocon
      • 6.5.10.1. Overview
      • 6.5.10.2. Financial Performance
      • 6.5.10.3. Treatment Benchmarking
      • 6.5.10.4. Strategic Initiatives

List of Tables

  • Table 1. List of secondary sources
  • Table 2. List of abbreviations
  • Table 3. U.S. diabetic ketoacidosis treatment market, by treatment, 2021 - 2033 (USD Million)
  • Table 4. U.S. diabetic ketoacidosis treatment market, by end use, 2021 - 2033 (USD Million)

List of Figures

  • Fig. 1 U.S. diabetic ketoacidosis treatment market segmentation
  • Fig. 2 Market research process
  • Fig. 3 Data triangulation techniques
  • Fig. 4 Primary research pattern
  • Fig. 5 Market research approaches
  • Fig. 6 Value-chain-based sizing & forecasting
  • Fig. 7 Market formulation & validation
  • Fig. 8 Market snapshot
  • Fig. 9 Competitive landscape
  • Fig. 10 U.S. diabetic ketoacidosis treatment market dynamics
  • Fig. 11 U.S. diabetic ketoacidosis treatment market: Porter's five forces analysis
  • Fig. 12 U.S. diabetic ketoacidosis treatment market: PESTLE analysis
  • Fig. 13 Treatment market, 2021 - 2033 (USD Million)
  • Fig. 14 Fluid replacement therapy market, 2021 - 2033 (USD Million)
  • Fig. 15 Electrolyte replacement therapy market, 2021 - 2033 (USD Million)
  • Fig. 16 Insulin therapy market, 2021 - 2033 (USD Million)
  • Fig. 17 Others market, 2021 - 2033 (USD Million)
  • Fig. 18 End Use market, 2021 - 2033 (USD Million)
  • Fig. 19 Hospitals market, 2021 - 2033 (USD Million)
  • Fig. 20 Ambulatory surgical centers (ASCs) market, 2021 - 2033 (USD Million)
  • Fig. 21 Homecare settings market, 2021 - 2033 (USD Million)
  • Fig. 22 Company categorization
  • Fig. 23 Company market position analysis
  • Fig. 24 Strategic framework